BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPUVIZ (aflibercept-yszy) is a biosimilar fusion protein approved in May 2024 that targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis. As a Samsung Bioepis product, it represents a follow-on biologic entry into the established aflibercept market. The specific indications for this biosimilar formulation are not yet fully detailed in available data.
Growth
Early-stage biosimilar in growth phase with competitive pressure of 30%, suggesting moderate market opportunity and potential for small-to-medium sized teams focused on market access and payer contracting.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPUVIZ roles are concentrated in commercial and market access functions given its biosimilar positioning and early growth stage. Career opportunity lies in navigating a competitive mature market, building payer relationships, and scaling market penetration against entrenched competitors.
Brand ManagerMarket Access Manager
Worked on OPUVIZ at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.